---
title: "GeoVax Raises $2.7 Million Net in Private Placement of Pre-Funded and Common Warrants"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286968346.md"
description: "GeoVax Labs has raised approximately $2.7 million through a private placement of pre-funded and common warrants. The deal includes 2,027,027 pre-funded warrants and Series A and B common warrants for up to 4,054,054 shares. A.G.P./Alliance Global Partners acted as the exclusive placement agent, earning a 7.0% fee. The funds will be used for working capital and general corporate purposes."
datetime: "2026-05-19T21:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286968346.md)
  - [en](https://longbridge.com/en/news/286968346.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286968346.md)
---

# GeoVax Raises $2.7 Million Net in Private Placement of Pre-Funded and Common Warrants

GeoVax Labs completed a private placement structured through a securities purchase agreement, yielding approximately $2.7 million in net proceeds. The transaction issued 2,027,027 pre-funded warrants, exercisable immediately at $0.0001 per share, and Series A and Series B common warrants covering up to 4,054,054 shares at $1.48 per share. Series A warrants expire in five years and Series B in eighteen months. A.G.P./Alliance Global Partners served as exclusive placement agent, earning a 7.0% fee plus expenses and a six-month tail. GeoVax plans to use proceeds for working capital and general corporate purposes.

**Agreement 1: GeoVax Raises $2.7 Million Net in Private Placement of Pre-Funded and Common Warrants**

-   **Agreement type**: Securities purchase agreement for private placement of pre-funded and common warrants
-   **Counterparty**: Purchasers
-   **Signed / Effective**: May 18 2026 / May 19 2026
-   **Duration / Termination**: Series A 5 years; Series B 18 months
-   **Reason**: Raise working capital and general corporate funds

**Agreement 2: GeoVax Engages A.G.P./Alliance Global Partners as Exclusive Placement Agent for Offering**

-   **Agreement type**: Placement agency agreement for private placement
-   **Counterparty**: A.G.P./Alliance Global Partners
-   **Signed / Effective**: May 18 2026 / May 18 2026
-   **Duration / Termination**: Through closing; 6-month tail
-   **Reason**: Engage agent to place securities in the Offering

Original SEC Filing: GeoVax Labs, Inc. \[ GOVX \] - 8-K - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GOVXW.US](https://longbridge.com/en/quote/GOVXW.US.md)
- [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats](https://longbridge.com/en/news/286807713.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)